Skip to content
10-Q

Quarterly Report

Dianthus Therapeutics, Inc. DNTH

0001690585-26-000022

← back to feed
Filed
May 5, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · May 1, 2026 54.67M sh
Shares Diluted Q1 2026 · Mar 31, 2026 48.03M sh
Shares Diluted Q1 2026 · Mar 31, 2025 35.79M sh
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$28.86M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$27.63M
Short Term Investments Q1 2026 · Mar 31, 2026 $483.59M
Short Term Investments Q1 2026 · Dec 31, 2025 $353.21M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $627.67M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $51.09M
Cash And Equivalents Q1 2026 · Mar 31, 2025 $10.12M
Stockholders Equity Q1 2026 · Mar 31, 2026 $1.2B
Stockholders Equity Q1 2026 · Dec 31, 2025 $493.4M
Stockholders Equity Q1 2026 · Mar 31, 2025 $328.61M
Stockholders Equity Q1 2026 · Dec 31, 2024 $352.48M
Current Liabilities Q1 2026 · Mar 31, 2026 $38.28M
Current Liabilities Q1 2026 · Dec 31, 2025 $30.73M
Total Liabilities Q1 2026 · Mar 31, 2026 $45.57M
Total Liabilities Q1 2026 · Dec 31, 2025 $37.52M
Current Assets Q1 2026 · Mar 31, 2026 $1.12B
Current Assets Q1 2026 · Dec 31, 2025 $409.44M
Total Assets Q1 2026 · Mar 31, 2026 $1.25B
Total Assets Q1 2026 · Dec 31, 2025 $530.92M
Eps Diluted Q1 2026 · Mar 31, 2026 −$0.85
Eps Diluted Q1 2026 · Mar 31, 2025 −$0.82
Eps Basic Q1 2026 · Mar 31, 2026 −$0.85
Eps Basic Q1 2026 · Mar 31, 2025 −$0.82
Sga Expense Q1 2026 · Mar 31, 2026 $12.47M
Sga Expense Q1 2026 · Mar 31, 2025 $7.34M
Rd Expense Q1 2026 · Mar 31, 2026 $34.53M
Rd Expense Q1 2026 · Mar 31, 2025 $27M
Net Income Q1 2026 · Mar 31, 2026 −$40.83M
Net Income Q1 2026 · Mar 31, 2025 −$29.51M
Operating Income Q1 2026 · Mar 31, 2026 −$46.53M
Operating Income Q1 2026 · Mar 31, 2025 −$33.18M